DK1268799T3 - Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet - Google Patents

Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet

Info

Publication number
DK1268799T3
DK1268799T3 DK01922997T DK01922997T DK1268799T3 DK 1268799 T3 DK1268799 T3 DK 1268799T3 DK 01922997 T DK01922997 T DK 01922997T DK 01922997 T DK01922997 T DK 01922997T DK 1268799 T3 DK1268799 T3 DK 1268799T3
Authority
DK
Denmark
Prior art keywords
cadherin
human
antibody
adverse effects
vascular permeability
Prior art date
Application number
DK01922997T
Other languages
Danish (da)
English (en)
Inventor
Daniel J Hicklin
Peter Bohlen
Fang Liao
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Application granted granted Critical
Publication of DK1268799T3 publication Critical patent/DK1268799T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01922997T 2000-03-31 2001-03-30 Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet DK1268799T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31
PCT/US2001/010505 WO2001075109A2 (en) 2000-03-31 2001-03-30 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability

Publications (1)

Publication Number Publication Date
DK1268799T3 true DK1268799T3 (da) 2009-07-06

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01922997T DK1268799T3 (da) 2000-03-31 2001-03-30 Antagonistiske antistoffer over for VE-cadherin uden ugunstige virkninger på den vaskulære permeabilitet

Country Status (12)

Country Link
US (4) US7371574B2 (https=)
EP (1) EP1268799B1 (https=)
JP (1) JP2003529370A (https=)
AT (1) ATE425255T1 (https=)
AU (1) AU2001249737A1 (https=)
CA (1) CA2404576A1 (https=)
CY (1) CY1109097T1 (https=)
DE (1) DE60137915D1 (https=)
DK (1) DK1268799T3 (https=)
ES (1) ES2323938T3 (https=)
PT (1) PT1268799E (https=)
WO (1) WO2001075109A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) * 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0604603A4 (en) * 1992-04-17 1996-09-25 Doheny Eye Inst ELEMENTS AND METHODS FOR THE PRODUCTION OF CADHERINES.
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
CY1109097T1 (el) 2014-07-02
ATE425255T1 (de) 2009-03-15
AU2001249737A1 (en) 2001-10-15
DE60137915D1 (de) 2009-04-23
US7371574B2 (en) 2008-05-13
EP1268799B1 (en) 2009-03-11
US20020160003A1 (en) 2002-10-31
WO2001075109A3 (en) 2002-05-16
US20080317750A1 (en) 2008-12-25
EP1268799A2 (en) 2003-01-02
WO2001075109A2 (en) 2001-10-11
JP2003529370A (ja) 2003-10-07
CA2404576A1 (en) 2001-10-11
US20080311121A1 (en) 2008-12-18
PT1268799E (pt) 2009-05-11
US20090060909A1 (en) 2009-03-05
ES2323938T3 (es) 2009-07-28

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DE69230545D1 (de) Antikörperderivate
MX2022008582A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
DK130791D0 (da) Monoklonale antistoffer, isaer for hb alc.
DE60334364D1 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DK0528931T3 (da) Humaniserede kimæriske anti-ICAM-1 antistoffer, fremgangsmåder til fremstilling deraf og anvendelse deraf
DK234789D0 (da) Antistoffer mod latente human papillomavirusproteiner, diagnostiske systemer og diagnostiske metoder
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
MX9203401A (es) Anticuerpos antagonistas de la interleukina-4 humana.
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DK0552296T3 (da) Monoklonale antistoffer fra mus
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DK0946873T3 (da) Fremgangsmåde til diagnose af allergisk bronkopulmonal aspergillose
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
KR900018365A (ko) 모노클로날 항체 및 이의 용도
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
EP0335134A3 (en) Mouse monoclonal antibody to human immunodeficiency virus gp41 protein
MX2007006895A (es) Deteccion de un anticuerpo terapeutico en animal de experimentacion.
AU4661293A (en) Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
WO2005118646A3 (en) Epitope directed selection of antibodies to murine tissue factor